C

Chiome Bioscience Inc
TSE:4583

Watchlist Manager
Chiome Bioscience Inc
TSE:4583
Watchlist
Price: 180 JPY 20% Market Closed
Market Cap: 11.2B JPY
Have any thoughts about
Chiome Bioscience Inc?
Write Note

Chiome Bioscience Inc
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Chiome Bioscience Inc
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
C
Chiome Bioscience Inc
TSE:4583
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CMIC Holdings Co Ltd
TSE:2309
Long-Term Investments
ÂĄ9.1B
CAGR 3-Years
26%
CAGR 5-Years
26%
CAGR 10-Years
34%
Precision System Science Co Ltd
TSE:7707
Long-Term Investments
ÂĄ55.2m
CAGR 3-Years
14%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Medinet Co Ltd
TSE:2370
Long-Term Investments
ÂĄ181.7m
CAGR 3-Years
-11%
CAGR 5-Years
0%
CAGR 10-Years
-11%
CellSource Co Ltd
TSE:4880
Long-Term Investments
ÂĄ152m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WDB coco Co Ltd
TSE:7079
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Chiome Bioscience Inc
Glance View

Market Cap
11B JPY
Industry
Life Sciences Tools & Services

Chiome Bioscience, Inc. engages in the development and sale of antibody drugs through the Autonomous Diversifying Library (ADLib) system. The company is headquartered in Shibuya-Ku, Tokyo-To and currently employs 37 full-time employees. The company went IPO on 2011-12-20. The firm operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.

Intrinsic Value
26.71 JPY
Overvaluation 85%
Intrinsic Value
Price
C

See Also

Back to Top